RecruitingNCT04743479

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer


Sponsor

Changhai Hospital

Enrollment

5,000 participants

Start Date

Dec 1, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

Pancreatic cancer is one of the most fatal malignancies with a 5-year survival rate of only \~6%\[1\]. The reasons for this high mortality rate can be attributed to several factors, of which perhaps the most important is delayed diagnosis due to vague symptoms and consequently missed opportunities for surgical resection. Therefore, the ability to detect pancreatic cancer at an early, more curable stage is urgently needed. Identifying risk factors and biomarkers of early pancreatic cancer could facilitate screening for individuals at higher than average risk and expedite the diagnosis in individuals with symptoms and substantially improve an individual's chance of surviving the disease. Thus, the investigators propose this longitudinal study entitled, "Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)" in order to generate clinical data sets and bank serial blood specimens of high risk individuals.


Eligibility

Min Age: 50 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study uses artificial intelligence to screen people at high risk of pancreatic cancer — before any symptoms appear — to detect the disease earlier when it's more treatable. **You may be eligible if...** - You were recently diagnosed with diabetes (within the past 3 years) - OR you have a family history of pancreatic cancer in a first-degree relative - OR you carry a genetic syndrome associated with pancreatic cancer risk (such as hereditary pancreatitis, BRCA mutations, Lynch syndrome, or others) - OR you have been diagnosed with chronic pancreatitis - You are willing to complete a detailed questionnaire and undergo screening **You may NOT be eligible if...** - You have already been diagnosed with pancreatic cancer - You are unwilling or unable to provide informed consent - You do not fall into any of the high-risk categories listed above Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESThigh-resolution MRI/CT examinations

Participants will undergo annual questionnaire survey, laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS).


Locations(1)

Shanghai Changhai Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04743479


Related Trials